In a matched analysis, rates of major adverse cardiac events were 3.10% for patients taking the JAK inhibitors tofacitinib (Xeljanz) or upadacitinib (Rinvoq) versus 4.27% for those taking TNF ...
A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic ...